Search

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.

Naxitamab was created at MSK and has received Breakthrough Therapy Designation from the FDA.

Scientists in all stages of their careers gathered recently to hear from Sharon Milgram speak about how attitudes and behaviors that can get in the way of a successful career.

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by MSK, Weill Cornell Medicine, and The Rockefeller University identified a vulnerability that opens the door to new treatments.

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce it has been named to the “Brands that Matter” list by Fast Company.

Learn about new insights into endometrial cancer discovered by MSK experts, including why the growing rates of this cancer are even more dangerous for Black women.

Learn why Black men should be especially mindful of prostate cancer risk.

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) that were reported online today in the New England Journal of Medicine.